Vertex Pharmaceuticals Appoints Jonathan Poole as EVP & CFO Effective Jan 1, 2027

Executive Transition Overview

On August 27, 2026, Vertex Pharmaceuticals Incorporated appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027.

Role Realignment

• Charles F. Wagner, Jr., who currently serves as EVP and Chief Operating & Financial Officer, will transition out of the CFO role on January 1, 2027, but will continue to serve as the company's Executive Vice President and Chief Operating Officer (COO).

Background of Jonathan Poole

• Current Role: Senior Vice President, Finance at Vertex Pharmaceuticals since March 2020.
• Prior Experience: Former CFO of Evelo Biosciences, Inc. (2018–2020) and Genocea Biosciences, Inc. (2014–2018), with earlier senior finance roles at Shire plc.
• Board Roles: Director and Audit Committee member at Acadia Pharmaceuticals Inc. (since March 2026); former director and Audit Committee chair at Codiak BioSciences.

Compensation and Agreement Terms

• Base Salary: $750,000 per year, effective January 1, 2027.
• Annual Incentive: Target annual bonus of 90% of base salary.
• Severance Protections: In the event of a termination without cause or for good reason, severance includes 100% of base salary, target annual bonus, unpaid prior-year bonuses, and up to 12 months of health premium coverage (COBRA).
• Change of Control: Enhanced provisions including 100% base and bonus, pro-rated bonus for the year of termination, and full accelerated vesting of outstanding equity awards (with uncertified performance awards deemed achieved at target).